Person:
ATAGÜNDÜZ, IŞIK

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

ATAGÜNDÜZ

First Name

IŞIK

Name

Filters

2017 - 201912020 - 20242
Reset filters

Settings

Author: TOPTAŞ, TAYFUR × Has files: true ×

Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    PublicationOpen Access
    Giant Intracranial Solitary Plasmacytoma
    (GALENOS YAYINCILIK) ATAGÜNDÜZ, IŞIK; Kara, Osman; Toptas, Tayfur; Atagunduz, Isik; Bozkurt, Suheyla; Sirikci, Onder; Tuglular, Tulin Firatli
  • Thumbnail Image
    PublicationOpen Access
    Molecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemia
    (SPANDIDOS PUBL LTD, 2017-12-13) TUĞLULAR, AYŞE TÜLİN; Kockan, Betul; Toptas, Tayfur; Atagunduz, Isik; Tuglular, Ayse Tulin; Ozer, Ayse; Akkiprik, Mustafa
    The present study aimed to detect the frequency of kinase domain (KD) mutations in order to evaluate their clinical significance and functional importance in 45 patients with chronic myeloid leukemia (CML) who were resistant to imatinib therapy. Sanger sequencing was used (45 patients), along with allele-specific oligonucleotide polymerase chain reaction (ASO-PCR; 3 patients), for the screening of mutations. BCR/ABL KD was amplified by nested PCR and sequencing was performed. Secondly, ASO-PCR was performed to confirm the results of the sequence analysis for E255K mutations. Mutations were detected in 11/45 patients (24.44%) via Sanger sequencing. D241G (4.4%), C369C (4.4%), K285N (2.2%), A380T (2.2%) and A366V (2.2%) mutations were detected. E255K (8.8%) was detected by ASO-PCR and Sanger sequencing. Mutations are a primary reason for suboptimal responses, loss of response and resistance to imatinib. In particular, the E255K mutation, which is characterized by resistance to imatinib and nilotinib, was detected in four patients. Analyzing the mutations and monitoring patients with CML may improve their prognosis and survival rate. ASO-PCR assays will be beneficial for the routine monitoring of mutations.
  • Thumbnail Image
    PublicationOpen Access
    The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia
    (2023-01-01) DEMİRTAŞ, DERYA; YANIK, AHMET MERT; ATAGÜNDÜZ, IŞIK; TOPTAŞ, TAYFUR; Candan O., Demirtas D., YANIK A. M., ATAGÜNDÜZ I., TOPTAŞ T.
  • Thumbnail Image
    PublicationOpen Access
    Peripheral T-Cell Lymphoma Coexisting with Autoimmune Hemolytic Anemia: Analysis of Clinical Features
    (2024-01-01) DEMİRTAŞ, DERYA; YANIK, AHMET MERT; YILMAZ, ASU FERGÜN; ATAGÜNDÜZ, IŞIK; TUĞLULAR, AYŞE TÜLİN; TOPTAŞ, TAYFUR; Candan O., Naghizada N., DEMİRTAŞ D., YANIK A. M., Salim S., Menguc M. U., Arikan F., YILMAZ A. F., ATAGÜNDÜZ I., TUĞLULAR A. T., et al.
    Autoimmune hemolytic anemia (AIHA) is characterized by the production of antibodies targeting red blood cells (RBCs) antigens. The diagnosis is based on the presence of a hemolytic anemia with a positive direct antiglobulin test (or Coombs test) and on the absence of any other hereditary or acquired cause of hemolysis, although direct antiglobulin test-negative cases are not quite uncommon (5% of 308 cases of AIHA recently reported by the Gruppo Italiano Malattie EMatologiche dell’Adulto [GIMEMA]) [1, 2]. AIHA can present in primary and secondary forms. Secondary AIHA generally includes factors such as connective tissue diseases, drugs, infections, and lymphomas [3]. Cases of AIHA accompanied by lymphoma are rare and are typically presented in the literature as case reports. Roughly one-fifth of AIHA patients have lymphoma, while 7–10% of lymphoma patients have co-existing AIHA, indicating a clinicopathological link between both diseases [4–6]. In clinical settings, AIHA is commonly associated with indolent B-cell lymphomas, whereas the combination of AIHA with peripheral T-cell lymphoma (PTCL) is rarely observed [7–11]. This study retrospectively analyzes the clinical data, laboratory characteristics, treatment processes, and prognosis of five patients with the coexistence of PTCL and AIHA who were diagnosed within the last 10 years in our center.